Presented at the International Congress of Cardiology, Hong Kong, Peoples Republic of China, February 24-26, 2012. This study was supported by the School of Pharmacy, the Chinese University of Hong Kong. The authors have no other funding, financial relationships, or conflicts of interest to disclose.”
“Objective: Post-cardiac arrest fever has been associated with adverse outcome before implementation of therapeutic hypothermia (TH), however the prognostic implications of post-hypothermia fever (PHF) in the era of modern post-resuscitation care including TH has not been thoroughly investigated.
The aim of the study was to assess the prognostic implication of PHF in
a large consecutive cohort of comatose survivors after out-of-hospital cardiac arrest (OHCA) treated with TH.
Methods: In the LY411575 cost period 2004-2010, NVP-LDE225 datasheet a total of 270 patients resuscitated after OHCA and surviving a 24-h protocol of TH with a target temperature of 32-34 degrees C were included. The population was stratified in two groups by median peak temperature (>= 38.5 degrees C) within 36 h after rewarming: PHF and no-PHF. Primary endpoint was 30-days mortality and secondary endpoint was neurological outcome assessed by Cerebral Performance Category (CPC) at hospital discharge.
Results: PHF (>38.5 degrees C)was associated
with a 36% 30-days mortality rate compared to 22% in patients without PHF, p(log-rank) = 0.02, corresponding to an adjusted hazard rate (HR) of 1.8 (95% CI: 1.1-2.7), p = 0.02). The maximum temperature (HR = 2.0 per degrees C above 36.5 degrees C (95% CI: 1.4-3.0), p = 0.0005) and the duration of PHF (HR = 1.6 per 8 h (95% CI: 1.3-2.0), p < 0.0001) were also independent predictors of 30-days mortality in multivariable
models. Good neurological outcome (CPC1-2) versus unfavourable outcome (CPC3-5) at hospital discharge was found in 61% vs. 39% in the PHF group compared to 75% vs. 25% in the No PHF group, p = 0.02.
Conclusions: Post-hypothermia fever >= 38.5 degrees C is associated with increased 30-days mortality, even after controlling for potential confounding factors. Avoidance of PHF as a therapeutic target should be evaluated in prospective BGJ398 randomized trials. (C) 2013 Elsevier Ireland Ltd. All rights reserved.”
“This study assesses the association between dietary transfatty acid (TFA) intake and the risk of selected cancers. Mailed questionnaires were completed between 1994 and 1997 in eight Canadian provinces by 1182 incident, histologically confirmed cases of the stomach, 1727 of the colon, 1447 of the rectum, 628 of the pancreas, 3341 of the lung, 2362 of the breast, 442 of the ovary, 1799 of the prostate, 686 of the testis, 1345 of the kidney, 1029 of the bladder, 1009 of the brain, 1666 non-Hodgkin’s lymphomas, 1069 leukemias, and 5039 population controls.